Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | CA7 | P43166 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.45 |
| ▸ | KDM5A | P29375 | 1/20 | 0.45 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 2/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.43 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10466297 | 0.85 | NUDT1 (0.52) | BRD4CA12CA1CA2CA7 | |
| SCHEMBL9434187 | 0.85 | BRD4 (0.49) | BRD4CA12CA1CA2CA7 | |
| SCHEMBL2113012 | 0.84 | CA12 (0.55) | CA12CA1CA2CA7CA9 | |
| SCHEMBL306569 | 0.84 | CA12 (0.50) | CA12CA1CA2CA7CA9 | |
| SCHEMBL27185753 | 0.83 | CA12 (0.49) | CA12CA1CA2CA7CA9 | |
| SCHEMBL30503143 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL28634780 | 0.81 | BRD4 (0.49) | BRD4KDM4EMAPTSMN1; SMN2CYP3A4 | |
| SCHEMBL31214492 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL2527607 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7CA9 | |
| SCHEMBL1260935 | 0.81 | CA12 (0.47) | CA12CA1CA2CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5322948-A | Reacting unsaturated diacid or derivative with hydroxylamine or a salt thereof to form N-hydroxy-2-aminobutane diacid derivative | HOECHST CELANESE CORPORATION (US) | 1994-06-21 | — | — | US | claimed |
| EP-0511446-A2 | Process for preparing pyridinecarboxylic acid derivatives | HOECHST CELANESE CORPORATION (US) | 1992-11-04 | — | — | EP | claimed |
| EP-0456504-A2 | Process for preparing pyridinecarboxylic acid derivatives | HOECHST CELANESE CORPORATION (US) | 1991-11-13 | — | — | EP | claimed |
| US-5047542-A | Reaction of ketoester with unsaturated aldehyde or ketone | HOECHST CELANESE CORPORATION (US) | 1991-09-10 | — | — | US | claimed |
| EP-0415767-A2 | Process for preparing pyridine carboxylic acid derivatives | HOECHST CELANESE CORPORATION (US) | 1991-03-06 | — | — | EP | claimed |
| US-4871859-A | REACTING KETOESTER WITH UNSATURATED ALDEHYDE OR KETONE AND AMMONIUM SALT IN SOLVENT AND DEHYDROGENATION CATALYST | HOECHST CELANESE CORPORATION | 1989-10-03 | — | — | US | claimed |
| WO-1989008103-A1 | PROCESS FOR PREPARING PYRIDINE CARBOXYLIC ACID ESTERS | HOECHST CELANESE CORPORATION (US) | 1989-09-08 | — | — | WO | claimed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-8008287-B2 | Use treating HIV and AIDS; tricyclic compounds such as those based on 5-sulfonamido-9-hydroxy-6,8-dihydrdo-7H-pyrrolo[3,4-g]quinoline-8-one | GILEAD SCIENCES, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20090306054-A1 | INTEGRASE INHIBITORS | GILEAD SCIENCES ,INC. (US) | 2009-12-10 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| US-20080058315-A1 | Integrase inhibitors | GILEAD SCIENCES, INC. | 2008-03-06 | — | — | US | disclosed |
| WO-2007136714-A2 | INTEGRASE INHIBITORS | GILEAD SCIENCES, INC. (US) | 2007-11-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058315-A1 | Integrase inhibitors | TYMP, DNTT, PAICS | BRD4 603/4885CA12 4732/4885CA1 4573/4885 |
| US-20090306054-A1 | INTEGRASE INHIBITORS | TYMP, POLR2E, CCNI | BRD4 1340/4885CA12 4724/4885CA1 4599/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.